199. Alendronate Discontinuation in Postmenopausal Women Treated for Osteoporosis
نویسندگان
چکیده
منابع مشابه
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
BACKGROUND Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years. METHODS The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received a...
متن کاملAlendronate improves QOL of postmenopausal women with osteoporosis
PURPOSE Postmenopausal osteoporosis causes bone fracture as well as pain, physical, psychological and socially adverse effects, which affects a patient's quality of life (QOL). The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-menopausal osteoporotic women. PATIENTS AND METHODS A total of 44 postmenopausal osteoporotic women (mean age 69.8 years) wit...
متن کاملEffects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis
OBJECTIVES Osteoporosis remains a clinical challenge. Teriparatide is an anabolic drug and alendronate is an antiresorptive agent; both are used in the treatment of osteoporosis. Comprehensive reviews investigating the comparative safety and efficacy of teriparatide versus alendronate are scarce. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs...
متن کاملPrimary osteoporosis in postmenopausal women
World Health Organization (WHO) defines natural menopause as at least 12 consecutive months of amenorrhea not due to physiologic and pathologic causes. Statistics show that the mean age of natural menopause is 51 years in industrialized nations, compared to 48 years in poor and non-industrialized nations. With the average life span extended to 70 years, most women will spend more than one third...
متن کاملHip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
Osteoporosis most commonly affects postmenopausal women, placing them at a significant risk of fractures. In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases in bone turnover markers together with greater increases in bone mineral density (BMD) are associated with greater reductions i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2014
ISSN: 1462-0332,1462-0324
DOI: 10.1093/rheumatology/keu113.002